Phase I trial to evaluate the tolerability and pharmacokinetics of NGX-426 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2006
At a glance
- Drugs Dasolampanel (Primary)
- Indications Migraine; Neuropathic pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors TorreyPines Therapeutics
- 08 Nov 2006 Status change
- 09 Aug 2006 New trial record.